Abbott LaboratoriesvsSS Innovations International

ABT and SSII stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$104.48

Value $182B

-0.22%
ABT's page

SSII

SS Innovations International Inc.

$1.31

Value $262M

-1.50%
SSII's page

Abbott Laboratories (ABT) has a market value of $182B and SS Innovations International (SSII) $262M. Over the last year, with dividends, ABT moved -17.7% and SSII -79.3%. Dividend yield: ABT 2.41%, SSII none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$182B

    SSII$262M

    ABT is 692 times SSII

  • Revenue, 12 months

    ABT$48.2B

    SSII$46M

    ABT is 1,051 times SSII

  • Net income, 12 months

    ABT$4.7B

    SSII-$14M

  • Operating margin

    ABT13.8%

    SSII-27.2%

    41.0 points apart

  • ROIC

    ABT6.3%

    SSII-17.5%

    23.8 points apart

  • P/E

    ABT38.6

    SSII–

  • Dividend yield

    ABT2.4%

    SSII0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-17.7%

SSII-79.3%

255075100DecFebAprJunAugOct
Returns by period
PeriodABTWith dividendsSSIIWith dividends
1 year since November 17, 2025-17.7%Price -19.6%-79.3%Price -79.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesSSIISS Innovations International

Valuation

ABTSSII
Valuation
Price$104.48$1.31
Market value$182B$262M
Enterprise value (EV)$208B$272M
P/E38.6–
P/E, 5-year median33.7–
P/B3.65.3
EV/EBIT31.4–
Free cash flow yield3.7%–

Results and growth

ABTSSII
Results and growth
Revenue, 12 months$48.2B$46M
Net income, 12 months$4.7B-$14M
Free cash flow, 12 months$6.8B-$17M
Earnings per share, 12 months$2.69-$0.07
Revenue growth, year on year5.7%105.7%
Revenue growth a year, past+5.1%over 5 years-69.1%over 3 years
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTSSII
Margins and returns on capital
Gross margin56.9%47.7%
Operating margin13.8%-27.2%
Net margin9.8%-31.5%
ROIC6.3%-17.5%
ROE9.1%-30.7%

Balance sheet

ABTSSII
Balance sheet
Cash$4.3B$8.1M
Total debt$31.2B$21M
Net debt / EBITDA3.3–
Interest cover6.7×-22.1×

Dividends and buybacks

ABTSSII
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or SSII

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or SS Innovations International?

By market value, Abbott Laboratories ($182B) is about 692.1 times SS Innovations International ($262M), at today's prices.

How did ABT and SSII stock do over the last 1 years?

Since November 17, 2025, ABT's price moved -19.6% and SSII's -79.3%. With dividends: ABT -17.7% (-17.7% a year), SSII -79.3% (-79.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or SSII?

The dividend yield at today's price is 2.41% for Abbott Laboratories and none for SS Innovations International. Over the last twelve months they paid $2.52 and – per share.

Which has the higher profit margins, Abbott Laboratories or SS Innovations International?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and -31.5% for SS Innovations International, and the operating margin 13.8% and -27.2%. Revenue was $48.2B and $46M.

Which is the better investment, Abbott Laboratories or SS Innovations International?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.